Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Verity Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of that agreement, Cumberland acquired U.S. rights to Sancuso (Granisetron) and assumed full commercial responsibility for the product – including its distribution, marketing, promotion, manufacturing and medical support activities.
Product Name : Sancuso
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 05, 2022
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Verity Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Study of Repeat Doses of SUSTOL in Adults
Details : Undisclosed
Product Name : Sustol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Cumberland Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Cumberland Pharmaceuticals Acquires Sancuso® From Kyowa Kirin North America
Details : Under the terms of the agreement, Cumberland will acquire U.S. rights to SANCUSO (Granisetron) and will assume full commercial responsibility for the product - including its marketing, promotion, distribution, manufacturing and medical support activities...
Product Name : Sancuso
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 01, 2022
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Cumberland Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Granisetron
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Granisetron
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Granisetron
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 30, 2021
Lead Product(s) : Granisetron
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Heron Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2019
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Heron Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Granisetron
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Tri-Service General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2015
Lead Product(s) : Granisetron
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Tri-Service General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2014
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Granisetron
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2013
Lead Product(s) : Granisetron
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable